Peter Wendell - Merck Independent Director
MRK Stock | MXN 2,172 10.50 0.48% |
Director
Mr. Peter C. Wendell is Independent Director of the Company. He is Managing Director, Sierra Ventures since 1982 Faculty, Stanford University Graduate School of Business since 1991. Senior Advisor and Director, WestBridge Crossover Fund, LLC since 2011 Charter Trustee, Princeton University Chairman, Princeton University Investment Co. from 2003 to 2008 and Director from 1998 to 2008. Mr. Wendell was also a director of Merck Sharp Dohme Corporationration from 2003 to 2009. since 2003.
Age | 67 |
Tenure | 21 years |
Phone | 908 740 4000 |
Web | https://www.merck.com |
Peter Wendell Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Wendell against Merck stock is an integral part of due diligence when investing in Merck. Peter Wendell insider activity provides valuable insight into whether Merck is net buyers or sellers over its current business cycle. Note, Merck insiders must abide by specific rules, including filing SEC forms every time they buy or sell Merck'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Wendell over six months ago Merck exotic insider transaction detected | ||
Peter Wendell over six months ago Acquisition by Peter Wendell of 270 shares of Merck subject to Rule 16b-3 |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Bernard Charles | Sanofi | 61 | |
Claudia Dyckerhoff | Roche Holding AG | 51 | |
Dinesh Paliwal | Bristol Myers Squibb | 60 | |
Beatrice Mauro | Roche Holding AG | 49 | |
Gottlieb Keller | Roche Holding AG | 64 | |
Christophe Babule | Sanofi | N/A | |
Gerald Storch | Bristol Myers Squibb | 61 | |
Marschall Runge | Eli Lilly and | 63 | |
Franklyn Prendergast | Eli Lilly and | 70 | |
Kathi Seifert | Eli Lilly and | 69 | |
Charles Holley | Amgen Inc | 61 | |
Alan Lacy | Bristol Myers Squibb | 64 | |
Robert Bertolini | Bristol Myers Squibb | 56 | |
Lewis Campbell | Bristol Myers Squibb | 67 | |
Laurie Glimcher | Bristol Myers Squibb | 63 | |
Bonnie Bassler | Sanofi | N/A | |
John Bell | Roche Holding AG | 65 | |
Anita Hauser | Roche Holding AG | 49 | |
Giovanni Caforio | Bristol Myers Squibb | 53 | |
Klaus Pohle | Sanofi | 76 | |
Suet Lee | Sanofi | 60 |
Management Performance
Return On Equity | 0.35 | |||
Return On Asset | 0.13 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director | ||
Craig Thompson, Independent Director | ||
Cristal Downing, Ex Officer | ||
Jennifer Zachary, General Counsel | ||
Rochelle Lazarus, Independent Director | ||
Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
Wendell Weeks, Independent Director | ||
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
Paul Rothman, Director | ||
Mary Coe, Director | ||
Adele Ambrose, Senior Vice President Chief Communications Officer | ||
Caroline Litchfield, Ex CFO | ||
Joseph Romanelli, IR Contact Officer | ||
Mirian GraddickWeir, Executive Vice President - Human Resources | ||
Peter Wendell, Independent Director | ||
John Noseworthy, Independent Director | ||
Jennifer Mauer, VP Communications | ||
Leslie Brun, Independent Director | ||
Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health | ||
Inge Thulin, Director | ||
Pamela Craig, Director | ||
Patricia Russo, Independent Director | ||
David Williams, Ex Officer | ||
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
Lisa LeCointeCephas, VP Officer | ||
Robert Davis, CFO and Executive VP | ||
Robert Kidder, Independent Director | ||
Thomas Cech, Independent Director | ||
Michael Nally, Chief Marketing Officer | ||
Peter Dannenbaum, VP Relations | ||
Clark Golestani, Executive Vice President CIO | ||
William Harrison, Lead Independent Director | ||
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
Steven Mizell, Chief Human Resource Officer | ||
Jim Scholefield, Chief Information and Digital Officer | ||
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
Adam Schechter, President of Global Human Health and Executive VP | ||
Carlos Represas, Independent Director | ||
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
Kenneth Frazier, Chairman, CEO and Pres | ||
Frank Clyburn, Chief Commercial Officer | ||
Robert JD, Pres Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.35 | |||
Return On Asset | 0.13 | |||
Profit Margin | 0.24 % | |||
Operating Margin | 0.38 % | |||
Current Valuation | 5.9 T | |||
Shares Outstanding | 2.54 B | |||
Shares Owned By Insiders | 0.10 % | |||
Shares Owned By Institutions | 76.37 % | |||
Price To Earning | 469.71 X | |||
Price To Book | 6.28 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |